A team from IIT-BHU is developing a revolutionary cell-based device using 3D bioprinting technology to potentially cure ...

But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show whether twice-daily oral dosing ...

A team at IIT (BHU) is developing a revolutionary cell-based medical device using 3D bioprinting technology aimed at curing ...

PTC Therapeutics may reeling from the failure of its amyotrophic lateral sclerosis (ALS) drug utreloxastat yesterday, but the ...

MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral ...

Widetrial is supporting an expanded access program (EAP) to bring MN-166 (ibudilast) to ALS patients ineligible for clinical ...

Despite the “unfortunate” failure, William Blair analysts do not believe that the utreloxastat readout will heavily affect ...

Study failed to meet primary and secondary efficacy endpoints - WARREN, N.J., Nov. 26, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced ...

ALS is a progressive neurodegenerative disease — and there is no cure. Brunner, who was running 3 miles a day at the onset of ...

New Jersey-based biopharma, PTC Therapeutics said its Phase II trial of utreloxastat for patients with amyotrophic lateral ...

PTC Therapeutics said on Tuesday its drug did not meet the main goal in a mid-stage trial evaluating it in patients with a type of fatal neurodegenerative disease called amyotrophic lateral sclerosis.

PTC Therapeutics will scrap development of its treatment for amyotrophic lateral sclerosis after it failed to meet a primary endpoint in a Phase 2 trial.